Favorable pregnancy outcome in a woman with extensive disseminated peritoneal leiomyomatosis.
Hagelauer. E E; Beck. M M; Rousset-Jablonski. C C; Ruaux. E E; Trecourt. A A; Rousset. P P; Gertych. W W
Key Findings
- GnRH‑agonist (gonadorelin) was used to shrink DPL lesions before pregnancy.
- Lesion size increased significantly during pregnancy despite prior treatment.
- Severe hypercalcemia occurred just before delivery, likely from a paraneoplastic cause.
- A planned C‑section at 36 weeks allowed safe delivery for both mother and baby.
Practical Outcomes
- For most biohackers, this case offers little direct guidance. It shows that GnRH‑agonist therapy may not prevent tumor growth during pregnancy and that DPL can complicate pregnancy, but it does not provide actionable protocols for longevity, metabolic health, or performance enhancement.
Summary
A 39‑year‑old pregnant woman with a rare condition called disseminated peritoneal leiomyomatosis (DPL) was treated with a GnRH‑agonist drug before pregnancy. Her tumors grew larger during pregnancy, and she developed severe high calcium levels before delivery. She safely delivered a baby by planned C‑section at 36 weeks.
Abstract
Disseminated peritoneal leiomyomatosis (DPL) is a rare and benign condition characterized by the progression of smooth muscle tumors across the peritoneal cavity. The etiology is not well understood and could include previous surgeries and hormonal stimulation. We report on a 39-year-old woman with extensive DPL at the end of her pregnancy. She was diagnosed in the context of amenorrhea and was initially treated by gonadotropin-releasing hormone (GnRH) agonist. During pregnancy, a significant increase in lesion size was observed. The day before the planned cesarean-section (C-section), she presented with severe hypercalcemia, which was probably from a paraneoplastic origin. The patient underwent a planned C-section at 36 weeks and 5 days of gestation by midline sub-umbilical laparotomy, allowing a safe delivery. This case provides insights for healthcare providers facing similar cases, considering that the obstetrical management of patients with DPL has not yet been defined.
Study Information
pubmed
2025
2025-10-03T00:00:00.000Z
10.1016/j.jogoh.2025.103045
12